Vertex Pharmaceuticals (VRTX) Competitors $390.30 -5.62 (-1.42%) Closing price 04:00 PM EasternExtended Trading$392.50 +2.20 (+0.56%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRTX vs. AMZN, AXSM, CRSP, GOOG, ISRG, MRNA, RGEN, ABBV, LLY, and PFEShould you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amazon.com (AMZN), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Alphabet (GOOG), Intuitive Surgical (ISRG), Moderna (MRNA), Repligen (RGEN), AbbVie (ABBV), Eli Lilly and Company (LLY), and Pfizer (PFE). Vertex Pharmaceuticals vs. Its Competitors Amazon.com Axsome Therapeutics CRISPR Therapeutics Alphabet Intuitive Surgical Moderna Repligen AbbVie Eli Lilly and Company Pfizer Amazon.com (NASDAQ:AMZN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are related large-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Does the media favor AMZN or VRTX? In the previous week, Amazon.com had 162 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 224 mentions for Amazon.com and 62 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.05 beat Amazon.com's score of 1.03 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amazon.com 155 Very Positive mention(s) 25 Positive mention(s) 22 Neutral mention(s) 14 Negative mention(s) 4 Very Negative mention(s) Positive Vertex Pharmaceuticals 43 Very Positive mention(s) 7 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, AMZN or VRTX? Amazon.com has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Do insiders and institutionals believe in AMZN or VRTX? 72.2% of Amazon.com shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 9.7% of Amazon.com shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, AMZN or VRTX? Amazon.com has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amazon.com, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmazon.com$637.96B3.86$59.25B$6.5635.21Vertex Pharmaceuticals$11.02B9.08-$535.60M$13.9927.90 Do analysts prefer AMZN or VRTX? Amazon.com presently has a consensus price target of $262.87, indicating a potential upside of 13.81%. Vertex Pharmaceuticals has a consensus price target of $497.10, indicating a potential upside of 27.36%. Given Vertex Pharmaceuticals' higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Amazon.com.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amazon.com 0 Sell rating(s) 1 Hold rating(s) 46 Buy rating(s) 2 Strong Buy rating(s) 3.02Vertex Pharmaceuticals 0 Sell rating(s) 13 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.56 Is AMZN or VRTX more profitable? Vertex Pharmaceuticals has a net margin of 31.86% compared to Amazon.com's net margin of 10.54%. Vertex Pharmaceuticals' return on equity of 23.91% beat Amazon.com's return on equity.Company Net Margins Return on Equity Return on Assets Amazon.com10.54% 23.84% 11.14% Vertex Pharmaceuticals 31.86%23.91%17.14% SummaryAmazon.com beats Vertex Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Vertex Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRTX vs. The Competition Export to ExcelMetricVertex PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$101.51B$3.08B$5.58B$9.81BDividend YieldN/A2.27%4.60%4.10%P/E Ratio27.9020.5630.2825.72Price / Sales9.08191.82388.6180.21Price / CashN/A42.0537.7558.93Price / Book5.837.598.456.01Net Income-$535.60M-$54.65M$3.25B$265.06M7 Day Performance3.91%5.43%4.05%2.80%1 Month Performance-17.37%6.75%4.32%1.68%1 Year Performance-17.21%31.59%36.25%29.59% Vertex Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRTXVertex Pharmaceuticals4.9439 of 5 stars$390.30-1.4%$497.10+27.4%-15.3%$101.51B$11.02B27.906,100Positive NewsAMZNAmazon.com4.592 of 5 stars$211.65-1.4%$262.45+24.0%+32.0%$2.25T$670.04B32.261,556,000Trending NewsAnalyst ForecastAXSMAxsome Therapeutics4.7261 of 5 stars$106.54+3.4%$172.33+61.8%+28.9%$5.25B$432.16M-18.46380CRSPCRISPR Therapeutics3.1814 of 5 stars$59.59+6.2%$70.07+17.6%+20.0%$5.15B$37.31M-13.18460Analyst RevisionGOOGAlphabet4.6508 of 5 stars$195.75+3.1%$215.19+9.9%+22.4%$2.37T$350.02B20.85190,200Trending NewsInsider TradeOptions VolumeAnalyst RevisionISRGIntuitive Surgical4.7122 of 5 stars$483.36+0.0%$595.95+23.3%+2.8%$173.27B$9.15B67.4115,638Positive NewsMRNAModerna4.459 of 5 stars$27.64+0.1%$45.61+65.0%-67.6%$10.69B$3.06B-3.675,800RGENRepligen4.8534 of 5 stars$116.50-2.0%$169.45+45.5%-22.7%$6.54B$634.44M-465.981,778Insider TradeABBVAbbVie4.7311 of 5 stars$197.05+0.9%$212.81+8.0%+5.3%$348.07B$56.33B93.8355,000Trending NewsAnalyst ForecastInsider TradeLLYEli Lilly and Company4.9993 of 5 stars$767.75+0.7%$1,012.56+31.9%-27.3%$727.63B$45.04B62.4747,000Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumePFEPfizer4.9616 of 5 stars$23.56+0.3%$28.28+20.0%-12.9%$133.95B$63.63B17.0781,000Trending News Related Companies and Tools Related Companies Amazon.com Alternatives Axsome Therapeutics Alternatives CRISPR Therapeutics Alternatives Alphabet Alternatives Intuitive Surgical Alternatives Moderna Alternatives Repligen Alternatives AbbVie Alternatives Eli Lilly and Company Alternatives Pfizer Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRTX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access